2021 Chimeric Antigen Receptor (CAR) T cell therapy research and development status – ResearchAndMarkets.com

DUBLIN – (COMMERCIAL THREAD)–The “Current state of research and development of chimeric antigen receptor (CAR) T cell therapy” the report was added to ResearchAndMarkets.com offer.

The global chimeric antigen receptor (CAR) T cell therapy market is expected to grow from $ 1.5 billion in 2021 to $ 7.6 billion by 2026, at a compound annual growth rate ( CAGR) of 39.1% in 2021-2026.

  • The North American CAR T cell therapy market is expected to grow from $ 751.5 million in 2021 to $ 3.5 billion by 2026, at a CAGR of 35.8% in 2021-2026.

  • The Asia-Pacific CAR T cell therapy market is expected to grow from $ 228.9 million in 2021 to $ 2.1 billion by 2026, with a CAGR of 56.0% in 2021-2026.

Descriptive company profiles of key industry players including AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Novartis AG, F. Hoffmann-La Roche, and Takeda Pharmaceutical Co., Ltd.

Design and evolution of CAR T cells

Chimeric antigen receptors (CARs, also called chimeric immunoreceptors, chimeric T cell receptors, artificial T cell receptors, or CAR-T) are modified receptors that graft an arbitrary specificity onto an immune effector cell (T cell). Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell, the transfer of their coding sequence being facilitated by retroviral vectors. Receptors are called chimeric because they are made up of parts from different sources.

FDA Product Approvals

There are five chimeric antigen receptor (CAR) T cell therapies currently approved by the US FDA. In March 2021, Bristol Myers Squibb launched its FDA-approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma.

In February 2021, Bristol Myers Squibb launched Breyanzi (lisocabtagene maraleucel) after receiving FDA approval for its commercialization in the US market. Breyanzi is a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma.

In July 2020, Kite Pharma, a subsidiary of Gilead Sciences, launched Tecartus after receiving FDA approval for its commercialization in the US market. Tecartus (brexucabtagene autoleucel, formerly KTE-X19), is the first and only chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adult patients with mantle cell lymphoma (MCL) in relapse or refractory.

On August 30, 2017, Novartis announced that the US FDA had approved the suspension of Kymriah (tisagenlecleucel) for intravenous infusion, formerly CTL019, the first chimeric antigen receptor (CAR) T cell therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second relapse or later.

On October 18, 2017, the US FDA approved Yescarta (axicabtagene ciloleucel) (Kite Pharma Inc.), a cell gene therapy, for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines. more systemic treatment, including diffuse large B cell lymphoma (DLBCL) not otherwise specified, mediastinal primary large B cell lymphoma, high grade B lymphoma, and DLBCL resulting from follicular lymphoma. Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. It is a genetically modified autologous T cell immunotherapy directed against CD19.

Main topics covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

  • Design and evolution of CAR T cells

  • FDA Product Approvals

  • Market analysis

  • Clinical applications of CAR T-Cell therapy

  • CAR for tumors of hematopoietic and lymphoid tissues

  • CAR T-Cell Therapy for solid tumors

  • Obstacles to product research and development

  • Clinical tests

Chapter 3 Introduction to Chimeric Antigen Receptor (CAR) T Cell Therapy

  • introduction

  • A Brief History of the Development of CAR T-Cell Therapy

  • Antigens

  • Exogenous antigens

  • Endogenous antigens

  • Autoantigens

  • Tumor antigens

  • Differentiation group

  • Lymphocytes

  • B cells

  • T cells

  • Adoptive cell transfer technologies (ACT)

  • Tumor infiltrating lymphocytes (TIL)

  • T cell receptors (TCRs)

  • Chimeric antigen receptors (CARs)

Chapter 4 Impact of COVID-19 on the Market

Chapter 5 Market Dynamics

  • Market dynamics

  • Selected Engines of the Global CAR T Cell Market

  • Tendencies

  • Selected Constraints of the Global CAR T Cell Market

Chapter 6 Current Production Methods, Latest Technological Advances and Future Direction

  • CAR T cell production

  • Step 1: Leukopheresis and T cell isolation

  • Step 2: T cell activation, transduction and modification of CAR T cells

  • Step 3: Extension of the modified CAR T cells

  • Overcoming CAR T Cell Manufacturing Challenges

  • Latest advances in production processes

  • Closed and automated production systems

  • End-to-end production systems and solutions

  • Key technologies used at the manufacturing stage

Chapter 7 Clinical Trials Using CAR T Cells and Related Technologies

  • introduction

  • Global clinical trials

  • Distribution of CAR T-Cell trials in the United States

  • Distribution of CAR T-Cell clinical trials in China

Chapter 8 Cancer Demographics: A Global Summary

  • Cancer: the disease

  • Epidemiology by cancer type / site

  • Global cancer incidence

  • Global cancer prevalence, 2020

  • Overview of global cancer mortality

  • Cancer epidemiology by region

  • Global cancer burden and cancer risk factors around the world

  • Tobacco use and statistics

  • Statistics on alcohol abuse and cancer

  • Obesity and Cancer Statistics

  • Infectious diseases and cancer

  • Hereditary genes: diseases and cancer

  • Sun, ultraviolet radiation and cancer

  • Hormones and cancer

Chapter 9 Global CAR T Cell Market Analysis

  • Ouicarta

  • Tecartus

  • Kymriah

  • Breyanzi

  • Abecma

Chapter 10 Regional Analysis

Chapter 11 Regulatory and legislative requirements

  • Mutual recognition procedure (MRP)

  • Decentralized Procedure (DCP)

  • Centralized Procedure (PC)

  • Published guidelines for the production and testing of cell therapy

Chapter 12 Patent Examination / New Developments

  • Complexities of patents and patent applications for biotechnology and pharmaceutical companies

  • Expected increase in patent litigation on personalized patient treatments

  • Company-specific intellectual property and patent information

  • Amgen

  • Avacta Life Sciences Ltd.

  • Bellicum Pharma inc.

  • Bluebird Bio

  • Celgene Corp.

  • Cellectis

  • Celyad SA

  • Editas Medicine Inc.

  • Eureka Therapeutics Inc.

  • Gilead Sciences Inc.

  • iCell Gene Therapeutics

  • Juno Therapeutics Inc. (A Celgene Co.)

  • Mustang Bio inc.

  • Biotech Noile-Immune

  • Novartis AG

Chapter 13 Global Competitive Market Landscape

  • Global CAR T Cell Market Share Analysis

  • Market share analysis

  • Product launches

  • Strategic initiatives

  • Mergers and Acquisitions

Chapter 14 Company Profiles

  • Abbvie inc.

  • Amgen

  • AstraZeneca

  • Avacta Life Sciences Ltd.

  • Bellicum Pharmaceuticals

  • Bluebird Bio

  • Bristol Myers Squibb

  • Cellectis

  • Celyad SA

  • Editas Medicine Inc.

  • Eureka Therapeutics Inc.

  • Formula Pharmaceuticals Inc.

  • Gilead Sciences

  • F. Hoffman-La Roche SA

  • Icell Gene Therapeutics

  • Mustang Bio inc.

  • Biotech Noile-Immune

  • Novartis AG

  • Protheragen Inc.

  • Puretech Health

  • Servier Laboratories

  • Takeda Pharmaceuticals

  • Transgene SA

For more information on this report, visit https://www.researchandmarkets.com/r/x1txa4


Source link

Comments are closed.